Effects of a pyroglutamyl pentapeptide isolated from fermented barley extract on atopic dermatitis-like skin lesions in hairless mouse. Issue 8 (2nd August 2020)

• Record Type: Journal Article
• Authors: Maruoka, Naruyuki; Watanabe, Bunta; Ando, Daigo; Miyashita, Masahiro; Kurihara, Tatsuo; Hokazono, Hideki
• Is Part Of: Bioscience, biotechnology, and biochemistry. Volume 84:Issue 8(2020)
• Page Start: 1696
• Page End: 1705
• Publication Date: 2020-08-02
• Subjects: Fermented barley extract -- pyroglutamyl pentapeptide -- atopic dermatitis -- stratum corneum hydration -- transepidermal water loss; Biotechnology -- Periodicals; Biochemistry -- Periodicals; 660.6
• DOI: 10.1080/09168451.2020.1762480
• Languages: English
• ISSNs: 0916-8451

Abstract

ABSTRACT: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritic and eczematous skin lesions. The skin of AD patients is generally in a dried condition. Therefore, it is important for AD patients to manage skin moisturization. In this study, we examined the effects of orally administered fermented barley extract P (FBEP), which is prepared from a supernatant of barley shochu distillery by-product, on stratum corneum (SC) hydration and transepidermal water loss (TEWL) in AD-like lesions induced in hairless mice using 2, 4, 6-trinitrochlorobenzene. Oral administration of FBEP increased SC hydration and decreased TEWL in the dorsal skin of this mouse model. Further fractionation of FBEP showed that a pyroglutamyl pentapeptide, pEQPFP comprising all -L-form amino acids, is responsible for these activities. These results suggested that this pyroglutamyl pentapeptide may serve as a modality for the treatment of AD. GRAPHICAL ABSTRACT: uf0001 A novel pyroglutamyl pentapeptide was isolated from FBE. Oral administration of the peptide improved epidermal barrier of AD-like hairless mice.